Inhibiting Alpha-Synuclein Nitration for Neurodegenerative Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Parkinson's lack effective interventions to slow, halt, or reverse disease progression, with nitration of α-synuclein contributing to protein aggregation and neurodegeneration, and existing inhibitors targeting free radical damage being non-specific and overwhelmed by high radical concentrations.
Innovation Solution
Identification and inhibition of α-synuclein nitration enzymes using specific compounds or biologics, which modulate the nitration enzymes to prevent deleterious nitration events, and development of methods for purifying and characterizing these enzymes to create targeted therapeutics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If existing inhibitors targeting free radical damage are used, then broad protection against oxidative stress is achieved, but the inhibitors are non-specific and overwhelmed by high radical concentrations
Solution Approach 1:
The patent extracts and isolates the specific nitration enzyme (nitrase) responsible for protein nitration from the general free radical damage pathway. By targeting this specific enzyme rather than general free radicals, the inhibitor can effectively block nitration without being overwhelmed by the high concentration of general reactive oxygen species present in neurodegenerative diseases.
Solution Approach 2:
The patent introduces a specific inhibitor as an intermediary substance that selectively binds to and inhibits the nitration enzyme. This intermediary approach allows for precise intervention in the nitration pathway without requiring direct neutralization of all free radicals, thereby achieving reliable inhibition despite high radical concentrations.
2Loss of energy
If non-specific free radical inhibitors are used, then broad antioxidant protection is provided, but the inhibitors cannot effectively slow or reverse disease progression due to being overwhelmed by high radical concentrations
Solution Approach 1:
The patent extracts the specific enzymatic nitration pathway from the general oxidative stress background, allowing targeted intervention. By focusing on the nitration enzyme rather than general free radicals, the inhibitor achieves effective disease progression slowing even when overall radical concentrations remain high.
Solution Approach 2:
The patent applies local quality by creating an inhibitor with specific affinity for the nitration enzyme's active site. This localized specificity allows the inhibitor to concentrate its effect precisely where nitration occurs, maximizing disease progression slowing without requiring high overall inhibitor concentrations.
3Object-affected harmful factors
If broad inhibition of free radical damage is attempted, then comprehensive antioxidant coverage is achieved, but the approach cannot specifically prevent α-synuclein nitration and aggregation
Solution Approach 1:
The patent introduces a specific inhibitor as an intermediary that selectively mediates between the nitration enzyme and its substrate α-synuclein. This intermediary approach enables precise blocking of nitration events while maintaining broad antioxidant coverage through the enzyme's selective inhibition mechanism.
Solution Approach 2:
The inhibitor exhibits local quality by having specific structural features that match the nitration enzyme's active site geometry and chemistry. This localized complementarity ensures high specificity for preventing α-synuclein nitration while the inhibitor's mechanism still provides broader antioxidant protection through enzyme inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the development of potent therapeutics that specifically inhibit α-synuclein nitration, potentially slowing or reversing neurodegenerative disease progression without broad inhibition of free radical damage, and opens new avenues for drug discovery targeting enzyme-mediated posttranslational modifications.
Implementation Method 1
Nitration of proteins has been linked to various disease conditions through inducement of agglomeration of proteins. Nitration is known to play a role in cardiovascular disease, oncology, and stroke.
Implementation Method 2
Recent studies have shown that familial ALS (fALS) mutations in SOD1 (Cu,Zn-superoxide dismutase-1) cause the mutated SOD1 to catalyze the nitration of its protein substrates. The enzyme activity of fALS mutant SOD1 is weak but demonstrates enzyme-catalyzed protein nitration.
Implementation Method 3
The present disclosure features methods of purification and characterization. Additionally, the present disclosure includes the use of nitration enzymes in screening for inhibitors, e.g., biologics or compounds, that modulate the nitration enzymes.
Data Source
AI summary
The present invention features methods for identifying treatments for neurodegenerative diseases, e.g., Parkinson's disease. Described are purification methods for synuclein nitration enzyme and screening methods for identifying agents that inhibit synuclein nitration enzyme activity.